Laboratorios Farmaceuticos Rovi, S.A. reported earnings results for the nine months ended September 30, 2023. For the nine months, the company reported sales was EUR 594.87 million compared to EUR 575.5 million a year ago. Net income was EUR 118.83 million compared to EUR 121.5 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
85 EUR | +0.35% | +7.05% | +41.20% |
Apr. 02 | Spain's Rovi Obtains US FDA Approval for Marketing Risvan as Schizophrenia Treatment | MT |
Mar. 12 | Rovi, Partners to Form Entity for Advanced Therapies R&D | MT |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+41.20% | 4.7B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- ROVI Stock
- News Laboratorios Farmaceuticos Rovi, S.A.
- Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023